The bottom line
Core issue: ALA is not EPA or DHA — and the label implies otherwise
The product is marketed with claims about "heart health," "brain function," "muscle recovery," and "joint health." Every RCT supporting those claims used EPA or DHA — not ALA. Selling flaxseed oil under these benefit claims is legal under India's current FSSAI supplement framework, but it is not honest.
Three different fatty acids. Two of them missing.
The omega3 family consists of three nutritionally relevant members. They are not interchangeable.
| Fatty acid | Chain length | Primary source | In this product? | Evidence base |
|---|---|---|---|---|
| ALA (α-linolenic acid) | 18:3n-3 | Flaxseed, chia, walnuts | Yes — 450 mg | Limited direct RCT evidence for claimed endpoints |
| EPA (eicosapentaenoic acid) | 20:5n-3 | Marine oil, algae oil | Zero | Strong: cardiovascular, anti-inflammatory, triglycerides |
| DHA (docosahexaenoic acid) | 22:6n-3 | Marine oil, algae oil | Zero | Strong: brain structure, retinal function, infant neurodevelopment |
How ALA is supposed to become EPA and DHA
ALA is a precursor. In theory, the body can elongate and desaturate it through a sequence of enzyme-catalysed reactions (delta-6 desaturase → elongase → delta-5 desaturase → further elongation/peroxidation) to produce EPA and eventually DHA. This pathway exists. The problem is its efficiency in practice.
The conversion problem — and why India makes it worse
In adult humans, apparent conversion rates from ALA to EPA are approximately 5–8%, and from ALA to DHA are under 1% in men, and up to 9% in premenopausal women (Burdge & Calder, 2005; Goyens et al., 2006). RCT
ALA → EPA → DHA: What 450 mg ALA per day actually delivers
Now add the India-specific context: the average Indian household cooks in sunflower or soybean oil, both of which are very high in linoleic acid (omega-6). Dietary omega-6 (LA) and ALA share the same delta-6 desaturase enzyme — when LA is abundant, it outcompetes ALA, suppressing conversion by an estimated 40–50% (Gerster, 1998). Observational
The average Indian diet has drifted to an omega-6:omega3 ratio of approximately 15:1 to 20:1, against the recommended 4:1 or lower. This is the single most important reason why an ALA supplement — consumed by someone cooking in refined sunflower oil — is particularly ineffective in the Indian dietary context.
The math at a typical Indian diet
450 mg ALA × 6% EPA conversion × (1 − 50% suppression from high-LA diet) = approximately 13–14 mg usable EPA per day. Cardiovascular RCT dosing threshold: 1,000–2,000 mg EPA+DHA per day. This product delivers roughly 1% of that target.
What the label says vs. what the evidence requires
| Label claim | Ingredient provided | Amount per serving (2 caps) | Evidence requirement | Gap |
|---|---|---|---|---|
| Heart health support | ALA (flaxseed oil) | 450 mg ALA | 1,000–2,000 mg EPA+DHA (meta-analysis) | ~99% short |
| Brain / cognitive function | ALA (flaxseed oil) | 450 mg ALA | 250–500 mg DHA (multiple RCTs) | ~99% short |
| Joint health / inflammation | ALA (flaxseed oil) | 450 mg ALA | 1,800–2,700 mg EPA+DHA (Fortin et al., 1995) | ~99% short |
| Muscle recovery | ALA (flaxseed oil) | 450 mg ALA | EPA + DHA — direct anti-inflammatory signalling via resolvins/protectins | Pathway absent |
| Immune support | ALA (flaxseed oil) | 450 mg ALA | ALA has modest immuno-modulatory data Observational | Partial — weakest claim |
| Omega-6 (LA) | Linoleic acid from flaxseed oil | 170 mg | Most Indians already over-consume omega-6 | Counterproductive in Indian diet context |
| Omega-9 (OA) | Oleic acid from flaxseed oil | 270 mg | Non-essential; body synthesises oleic acid endogenously | Filler — not harmful, not needed |
The label correctly discloses that the omega3 source is ALA and that the oil is from flaxseed. It does not hide the ingredient. The problem is what comes next: benefit claims copied from marine omega3 research, applied to a product that delivers none of the fatty acids those trials actually used. Under the FSSAI's current supplement regulations, this is permitted. From an evidence standpoint, it is misleading.
Why "plant omega3" is the most consistently misleading claim in Indian supplements
ALA is an essential fatty acid — the body cannot synthesise it, so dietary intake matters. ALA has its own physiological roles: it participates in membrane phospholipid composition, has modest anti-inflammatory activity via alpha-linolenic acid-derived lipid mediators, and appears to have some cardiovascular benefit at high intakes when modelling population-level data. Observational
None of this makes it an omega3 supplement in any clinically meaningful sense of that phrase. When a consumer buys "omega3" based on recommendations from a doctor, dietician, or the general health media, they are responding to evidence built on EPA and DHA — not ALA. The clinical literature is unambiguous.
What Indian vegetarians actually need
India has the world's largest vegetarian population, and this creates a real clinical problem: the main dietary sources of EPA and DHA are fatty fish (hilsa, mackerel, sardine, tuna) and to a lesser extent, eggs. Strict vegetarians, vegans, and many Hindu, Jain, and certain regional communities who avoid fish have systematically lower EPA and DHA status than omnivores. Observational
The supplement solution for this group already exists and is commercially available: algae oil. EPA and DHA originate in microalgae — fish accumulate these fatty acids by consuming algae in the marine food chain. Algae-derived omega3 supplements provide preformed EPA and DHA, identical in structure and bioavailability to marine-sourced EPA and DHA, without any fish in the supply chain. This is not a compromise position. It is the same molecule.
A product like Himalayan Organics Plant Omega 3-6-9 implicitly substitutes for algae oil in the minds of vegetarian consumers looking for a vegan EPA/DHA source. It does not deliver what they are looking for.
What the trials actually show for ALA vs. EPA/DHA
ALA and cardiovascular outcomes
The PREDIMED trial found benefit from a Mediterranean dietary pattern high in ALA-containing walnuts, but the intervention involved the whole diet pattern — not ALA supplementation in isolation. RCT The Alpha Omega Trial (n=4,837), which added ALA supplementation to patients with prior myocardial infarction, found no significant reduction in major cardiovascular events. RCT
EPA + DHA and cardiovascular outcomes
The REDUCE-IT trial (n=8,179) found a 25% reduction in major cardiovascular events with 4g/day icosapentaenoic acid (pure EPA). RCT JELIS (n=18,645) found a 19% reduction in major coronary events with 1.8g/day EPA added to statin therapy. RCT The evidence base for EPA and DHA is among the most replicated in clinical nutrition.
DHA and brain health
DHA constitutes approximately 97% of the omega3 fatty acids in the brain and 93% in the retina. RCTs using DHA supplementation in adults show modest but consistent improvements in processing speed and memory in older adults (Yurko-Mauro et al., 2010, MIDAS trial, n=485). RCT No equivalent RCT exists for ALA supplementation and cognitive outcomes.
ALA and conversion in women vs. men
Premenopausal women convert ALA to EPA at approximately 21% and to DHA at approximately 9% — meaningfully higher than adult men, due to oestrogen upregulating delta-6 desaturase expression (Burdge & Calder, 2005). RCT This means the product is substantially less ineffective for premenopausal women than for men — though still far below what algae oil would deliver directly. Postmenopausal women and men derive near-zero DHA from this product.
Score note — "Value" rated 7/10
The product costs approximately ₹10/serving for 450 mg ALA. If your only goal is ALA intake — not EPA or DHA — this is a reasonable-cost delivery vehicle. One tablespoon of flaxseed oil provides 7,200 mg ALA for about ₹6–8. The capsule format is less economical but more convenient. The 7/10 value score reflects ALA delivery cost only; it does not indicate clinical value for the marketed endpoints.
No published COA. No purity certification. Unknown oxidation status.
| Test | Standard | Status |
|---|---|---|
| Active ingredient accuracy (ALA mg) | ±10% of label | Not publicly verified |
| Oil freshness (TOTOX, PV, AV) | TOTOX <26; PV <5 meq/kg | Not publicly verified |
| Heavy metals (Pb, Cd, Hg, As) | FSSAI / WHO limits | Not publicly verified |
| Microbial contamination | USP / FSSAI | Not publicly verified |
| Pesticide residues (flaxseed oil) | EU/Codex MRL | Not publicly verified |
| Per-batch COA published | Best practice | No |
Flaxseed oil is high in polyunsaturated fat and is particularly susceptible to oxidative rancidity. The TOTOX (total oxidation) value — a composite of peroxide value and anisidine value — is the standard measure of oil freshness. No TOTOX data is publicly available for this product. Rancid flaxseed oil delivers not only degraded ALA but also oxidised lipid byproducts (aldehydes, malondialdehyde) that are biologically active in ways that are not beneficial. This is a genuine quality concern for any ALA-based supplement, particularly one sold through Amazon India with no information on cold-chain handling or batch dating.
Climate storage risk — particularly relevant for Indian consumers
Flaxseed oil oxidises rapidly when exposed to heat or light. During Indian summer (March–June), last-mile delivery vehicles in cities like Delhi, Mumbai, Chennai, and Hyderabad regularly reach 45–50°C interior temperatures. ALA oxidises far more readily than saturated fats. There is no information on whether this product is packaged in a light-blocking, oxygen-flushed format or whether the supply chain maintains cold-chain handling. IFOS-certified fish oil manufacturers must meet specific TOTOX standards — no equivalent voluntary programme exists for flaxseed oil supplements in India, and this brand has not enrolled in one.
INR pricing table — ALA vs. EPA+DHA options for Indian vegetarians
| Product | omega3 type | Per serving (active) | Pack price (INR) | ₹ per 100mg active omega3 | 3rd-party tested? |
|---|---|---|---|---|---|
| Himalayan Organics Plant Omega 3-6-9 (this product) | ALA only | 450 mg ALA (0 mg EPA, 0 mg DHA) | ₹599 / 60 ct | ₹4.44 / 100mg ALA — but ALA has <8% conversion to EPA | No |
| Testa omega3 Algae Oil | EPA + DHA (algae) | 330 mg DHA + 165 mg EPA per cap | ~₹1,499 / 60 ct | ₹6.06 / 100mg EPA+DHA — directly bioavailable | IFOS certified |
| HK Vitals Fish Oil 1000mg | EPA + DHA (marine) | 180 mg EPA + 120 mg DHA per cap | ₹699 / 60 ct | ₹2.33 / 100mg EPA+DHA | No COA published |
| Carbamide Forte omega3 Triple Strength | EPA + DHA (marine) | 360 mg EPA + 240 mg DHA per cap | ₹999 / 60 ct | ₹1.67 / 100mg EPA+DHA | Partial COA |
| Raw flaxseed oil (cold-pressed) | ALA only | ~7,200 mg ALA per tbsp | ~₹300 / 250ml | ₹0.08 / 100mg ALA | No |
For the Indian vegetarian or vegan consumer who cannot eat fish and is looking for genuine EPA + DHA supplementation, algae oil is the only scientifically valid option. The cost per 100 mg of directly bioavailable EPA+DHA from an algae supplement (approximately ₹6–8) is higher than flaxseed ALA, but it is the only way to actually deliver the fatty acids that the claimed benefits require.
Dietary sources of ALA in India (for context)
If your goal is ALA specifically — not EPA or DHA — the following common Indian foods are excellent sources and cost a fraction of any supplement: 1 tablespoon of ground flaxseed (alsi) provides ~2,300 mg ALA; a small handful of walnuts (~30g) provides ~2,600 mg ALA; 1 tablespoon of mustard oil provides ~820 mg ALA. There is no supplementation argument for paying ₹599 for 450 mg ALA/day when flaxseeds cost ₹60–80 per 500g and provide far more per gram.
What to buy instead — for each use case
See the full omega3 category index → for all 8 reviewed products with comparative scores and pricing.
Buy / don't buy
Buy if
- You specifically want ALA supplementation (not EPA or DHA) and prefer capsule format to flaxseed oil
- You are a premenopausal woman with high dietary omega-6 who uses this as a minor ALA top-up alongside algae oil
- Your doctor has specifically recommended ALA, not EPA/DHA (rare clinical scenario)
Don't buy if
- You want omega3 for cardiovascular, brain, or joint health — these require EPA and DHA
- You are a vegetarian or vegan looking for a fish-free omega3 supplement (get algae oil instead)
- You are male — ALA-to-DHA conversion is under 1% and the benefits are essentially nil
- You cook with sunflower or soybean oil — your omega-6 intake will suppress even the limited ALA conversion that does occur
- You are pregnant or breastfeeding — DHA is critical for foetal and infant brain development, and ALA supplementation cannot reliably supply it
Storage note for those who proceed
Flaxseed oil oxidises rapidly. Store capsules in the refrigerator, away from light. Do not leave in a car or near a kitchen stovetop. Check the expiry date on receipt — do not buy close-dated stock via Amazon (batch dates are rarely shown on listing pages). Smell a capsule when you open the pack: rancid flaxseed oil smells sharp and fishy-stale. If it does, discard the bottle.
Three changes that would make this product honest
Reformulate with algae oil — not flaxseed oil
Himalayan Organics already positions itself as a premium plant-based brand. The only way to deliver a vegan omega3 supplement that can legitimately claim cardiovascular and cognitive benefits is to use algae-derived EPA and DHA. This is more expensive to source but it is the only scientifically defensible formulation. The "vegan omega3" market in India is genuinely underserved — a properly formulated algae oil product from this brand at ₹799–999/30ct would have a legitimate market position.
Remove all cardiovascular, brain, and joint benefit claims from the label
The current label copies claim language from EPA/DHA research. If the product remains ALA-based, the only claims that have direct evidence support are: "source of ALA, an essential omega3 fatty acid" and "contributes to daily omega3 intake." Removing the heart, brain, joint, and muscle recovery claims would make the label accurate. It would also significantly reduce the product's commercial appeal — which is precisely the problem.
Publish a TOTOX-verified COA for every batch
Flaxseed oil quality varies significantly by pressing method, storage conditions, and batch age. Publish a per-batch Certificate of Analysis from a NABL-accredited lab that includes peroxide value (PV), anisidine value (AV), and TOTOX. This costs approximately ₹3,000–5,000 per batch and takes 5–7 working days. It is not a barrier for any supplement company with a functioning supply chain. It is table stakes for a product asking Indian consumers to put it in their body.
References & citations
- Gerster H. (1998). Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res, 68(3):159–73. PubMed →
- Burdge GC, Calder PC. (2005). Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev, 45(5):581–97.
- Goyens PL et al. (2006). Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr, 84(1):44–53. RCT
- Arterburn LM et al. (2006). Algae-derived DHA and EPA are bioequivalent to fish oil sources. Prostaglandins Leukot Essent Fatty Acids, 74(5):303–15. RCT
- Bhatt DL et al. (2019). REDUCE-IT: Cardiovascular risk reduction with icosapentaenoic acid (EPA 4g/day). NEJM, 380(1):11–22. RCT
- Yokoyama M et al. (2007). JELIS trial: EPA and major coronary events in hypercholesterolaemic patients. Lancet, 369(9567):1090–98. RCT
- Yurko-Mauro K et al. (2010). MIDAS trial: DHA supplementation and cognitive function in healthy older adults. Alzheimers Dement, 6(6):456–64. RCT
- Fortin PR et al. (1995). Validation of a meta-analysis: omega3 fatty acids in arthritis. J Clin Epidemiol, 48(11):1379–90.
- Simopoulos AP. (2010). The omega-6/omega3 fatty acid ratio: health implications. OCL Oilseeds Fats Crops Lipids, 17(5):267–75.
- Sacks FM et al. (2017). Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the AHA. Circulation, 136(3):e1–e23.